Risks of colorectal and other cancers after endometrial cancer for women with lynch syndrome

Journal of the National Cancer Institute

Volumn 105, Issue 4, 2013, Pages 274-279

  Win, Aung Ko ^a   Lindor, Noralane M ^c   Winship, Ingrid ^b,d   Tucker, Katherine M ^e   Buchanan, Daniel D ^f   Young, Joanne P ^f   Rosty, Christophe ^f,h   Leggett, Barbara ^g,h,i   Giles, Graham G ^j   Goldblatt, Jack ^k   MacRae, Finlay A ^d   Parry, Susan ^l,m   Kalady, Matthew F ⁿ   Baron, John A ^o   Ahnen, Dennis J ^p   Marchand, Loic Le ^q   Gallinger, Steven ^r,s   Haile, Robert W ^t   Newcomb, Polly A ^u   Hopper, John L ^a   Jenkins, Mark A ^a   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MAYO CLINIC   (United States)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^g University of Queensland ^*  (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^j CANCER EPIDEMIOLOGY CENTRE   (Australia)

^k UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^l AUCKLAND CITY HOSPITAL   (New Zealand)

^m MIDDLEMORE HOSPITAL   (New Zealand)

ⁿ Digestive Disease Institute   (United States)

^o UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^r MOUNT SINAI HOSPITAL   (Canada)

^s CANCER CARE ONTARIO   (Canada)

^t UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^u USA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; GENETIC RISK; GEOGRAPHIC DISTRIBUTION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; KIDNEY CANCER; KIDNEY PELVIS CANCER; MAJOR CLINICAL STUDY; MISMATCH REPAIR; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; URETER CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASMS; NUCLEAR PROTEINS; RISK; SKIN NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84875036048     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs525     Document Type: Article

References (34)

1. Gruber SB, Thompson WD. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev. 1996;5(6): 411-417.
2. Ollikainen M, Abdel-Rahman WM, Moisio A-L, et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol. 2005;23(21): 4609-4616.
3. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66(15): 7810-7817.
4. Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A. 2003;100(10): 5908-5913.
5. Leenen CH, van Lier MG, van Doorn HC, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70years. Gynecol Oncol. 2012;125(2): 414-420.
6. Vasen HFA, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1999;116(6): 1453-1456.
7. Kempers MJE, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12(1): 49-55.
8. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30(9): 958-964.
9. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4): 261-268.
10. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16): 1790-1795.
11. Aarnio M,Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Lifetime risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64(6): 430-433.
12. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5): 424-425.
13. Newcomb PA, Baron J, Cotterchio M, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(11): 2331-2343.
14. Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst. 2012;104(18): 1363-1372.
15. Southey MC, Jenkins MA, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005;23(27): 6524-6532.
16. Smith L, Tesoriero A, Mead L, et al. Large genomic alterations in hMSH2 and hMLH1 in early-onset colorectal cancer: identification of a large complex de novo hMLH1 alteration. Clin Genet. 2006;70(3): 250-252.
17. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135(2): 419-428.
18. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
19. Parkin DM, Muir CS, Whelan SL, Gao Y-T, Ferlay J, Powell J. Cancer incidence in five continents, Vol VI. In: IARC Scientific Publications No. 120. Lyon, France: International Agency for Research on Cancer; 1992.
20. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents, Vol VII. In: IARC Scientific Publications No. 143. Lyon, France: International Agency for Research on Cancer; 1997.
21. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, Vol VIII. In: IARC Scientific Publications No. 155. Lyon, France: International Agency for Research on Cancer; 2002.
22. Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents, Vol IX. In: IARC Scientific Publications No. 160. Lyon, France: International Agency for Research on Cancer; 2007.
23. Freedman DM, Curtis RE, Travis LB, Fraumeni JF Jr. New malignancies following cancer of the uterine corpus and ovary. In: Curtis RE, Freedman DM, Ron E, et al., eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006, 231-256.
24. Breslow NE, Day NE. Statistical methods in cancer research. In: Heseltine E (ed). Volume II - The Design and Analysis of Cohort Studies. Scientific Publications No. 82. Lyon, France: International Agency for Research on Cancer; 1987, 91-103.
25. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60(7): 950-957.
26. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
27. Walsh MD, Buchanan DD, Cummings MC, et al. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res. 2010;16(7): 2214-2224.
28. Lotsari JE, Gylling A, Abdel-Rahman WM, et al. Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. Breast Cancer Res. 2012;14(3):R90.
29. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2): 75-89.
30. Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. In press.
31. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22): 2304-2310.
32. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010;102(3): 193-201.
33. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006;296(12): 1479-1487.
34. Keogh LA, van Vliet CM, Studdert DM, et al. Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications? Med J Aust. 2009;191(5): 255-258.